Abstract Number: 1989 • ACR Convergence 2022
Predictors of Flare in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
Background/Purpose: Long term use of conventional synthetic DMARDs (csDMARDs) and biologics in RA has clinical risks including infection and malignancy. Few RCTs and real-world studies…Abstract Number: 2208 • ACR Convergence 2022
Diagnostic Performance of Hip Ultrasound in Calcium Pyrophosphate Deposition Disease
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a chronic and potentially incapacitating disease. The reference standard for its diagnosis is the identification of calcium pyrophosphate…Abstract Number: 0154 • ACR Convergence 2021
Utilization of Magnetic Resonance Imaging in Early Rheumatoid Arthritis: Results from a Population-based Cohort (1999-2014)
Background/Purpose: Early diagnosis and treatment initiation improve outcomes for patients with rheumatoid arthritis (RA). Delays to diagnosis and treatment affect patients with seronegative vs seropositive…Abstract Number: 0813 • ACR Convergence 2020
Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors
Background/Purpose: Seropositivity / seronegativity in RA may have influence on response to bDMARDs or tsDMARDs. There is incomplete knowledge of differences in efficacy of JAK…